China Pharma Holdings (CPHI) EBITDA (2010 - 2026)

China Pharma Holdings (CPHI) has reported EBITDA for 17 consecutive years, with -$1.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 119.57% year-over-year to -$1.4 million; the trailing twelve-month figure through Jun 2026 stood at -$4.4 million (down 18.56% YoY), and the FY2025 full-year result was -$3.2 million, up 29.41% from the prior year.
• EBITDA eased to -$1.4 million in Q2 2026 per CPHI's latest filing, from -$1.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$397479.0 in Q1 2023 and bottomed at -$1.4 million in Q2 2026.
• Historically, EBITDA has averaged -$926547.2 across 5 years, with a median of -$913885.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA jumped 56.4% in 2023, then sank 204.95% in 2024.
• Over 5 years, EBITDA stood at -$1.2 million in 2022, then fell by 1.32% to -$1.2 million in 2023, then dropped by 0.97% to -$1.2 million in 2024, then decreased by 0.35% to -$1.2 million in 2025, then slipped by 19.3% to -$1.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$1.4 million, -$1.1 million, and -$1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.